The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 15)
Research Grant, 2017
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease (PD). The FDA has indicated that the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) is an acceptable combined cognitive-functional outcome for use in clinical trials; however, the CDR-SOB has ...
Researchers: Daniel Weintraub, MD
Research Grant, 2017
While significant strides have been made toward therapies that can prevent, slow or stop Parkinson's disease (PD) progression, no currently approved Parkinson's treatment can do this. Therapeutics that target alpha-synuclein, the sticky protein that clumps in the brains of people with PD, may modify the course of disease. We are developing a new therapy that aims to prevent alpha-...
Researchers: Saar I. Gill, MD, PhD
Access to Data and Biospecimens, 2017
An 8-protein panel for diagnosis of Parkinson's Disease: Sample request for replication in PDBP and PPMI
We have previously found a panel of 8 proteins that can be measured in the blood that together distinguish people who have Parkinson's Disease vs. people who do not. We are trying to see whether the results we found at our clinical site (University of Pennsylvania) extend to PD patients from other clinical sites.
An 8-protein panel of blood-based biomarkers wil...
Researchers: Alice Chen-Plotkin,
Improved Biomarkers and Clinical Outcome Measures, 2016
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology of PD occurs outside of the motor system, namely in the olfactory bulbs (brain regions that detect smell) and the brainstem (brain region that controls involuntary functions), we are probing the functi...
Access to Data and Biospecimens, 2015
Mixed pathology is common in all neurodegenerative diseases including Parkinson's disease (PD). Three cerebrospinal fluid (CSF) biomarkers, Ab1-42, t-tau and p-tau181, provide an index to the hallmark pathologic markers of Alzheimer's disease (AD) pathology, namely, plaques and tangles. Thus we measured these three biomarkers in CSF of BioFIND PD and healthy matched controls i...
Researchers: Leslie Shaw, PhD